Search database
Filter
1643
Text search: drug trial
Featured
Language
Document type
866
300
294
79
33
32
18
8
4
3
2
1
Countries
95
68
51
39
25
24
23
23
22
20
20
19
19
18
17
17
14
14
14
13
13
13
12
11
11
10
9
8
8
8
7
7
7
7
6
6
6
5
5
5
4
4
4
4
4
3
3
3
3
3
3
3
3
3
3
3
2
2
2
2
2
2
2
2
2
2
2
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Authors & Publishers
274
119
71
68
36
35
28
25
23
22
21
16
15
14
12
9
8
8
8
8
7
7
7
6
6
6
6
6
6
6
5
5
5
5
5
5
5
5
4
4
4
4
4
4
4
4
4
4
4
4
4
4
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Publication Years
Category
445
212
92
77
28
14
11
Toolboxes
273
209
123
120
103
62
42
42
41
40
21
18
16
16
12
12
9
8
6
6
5
4
4
3
3
 Download
  View PDF
 Add to my

2025 Update of the Drug Resistance Mutations in HIV-1

Wensing, A.M., V.Calvez, F. Ceccherini-Silberstein, et al. (2025) CC
Topics in Antiviral Medicine, March 4, 2025
 Download
  View PDF
 Add to my

Guidelines for the programmatic management of drug-resistant tuberculosis

World Health Organization (2011) C_WHO
This 2011 update of Guidelines for the programmatic management of drug-resistant tuberculosis is intended as a tool for use by public health professionals working in response to the Sixty-second World Health Assembly’s resolution on prevention an ... more
 Download
  View PDF
 Add to my

DR-TB drugs under the microscope: Sources and prices for drug-resistant tuberculosis medicines
recommended

Médecins sans Frontières (2022) C_WHO
Issue Brief 8th edition.
 Download
  View PDF
 Add to my

Guidelines on programmatic management of drug resistant tuberculosis in Ethiopia
recommended

Ministry of Health Ethiopia (2014) CC
2nd edition
 Download
  View PDF
 Add to my

Guidelines for the treatment of drug-susceptible tuberculosis and patient care, 2017 up-date

H. Schünemann, S.T. Aung, F. Bonsu et al. World Health Organisation (WHO) (2017) C_WHO
 Download
  View PDF
 Add to my

International Standards for the Treatment of Drug Use Disorders
recommended

World Health Organization, United Nations Office on Drugs and Crime (2017) C2
 Download
  View PDF
 Add to my

The role of psychosocial interventions in drug treatment

European Monitoring Centre for Drugs and Drug Addiction (2016) C2
Perspectives on drugs
 Download
  View PDF
 Add to my

Guidelines for the use of delamanid in the treatment of drug-resistant TB in India
recommended

Ministry of Health & Family Welfare, India; World Health Organization (WHO) (2018) C1
 Download
  View PDF
 Add to my

Sensitive diagnostic tools and targeted drug administration strategies are needed to eliminate schistosomiasis

Amoah A.S., P. T. Hoekstra, M. Casacuberta-Partal, (2020) C2
Lancet Infect Dis 2020 Published Online May 5, 2020 https://doi.org/10.1016/ S1473-3099(20)30254-1
 Download
  View PDF
 Add to my

WHO treatment guidelines for isoniazid-resistant tuberculosis: Supplement to the WHO treatment guidelines for drug-resistant tuberculosis
recommended

World Health Organization WHO (2018) C_WHO
The new WHO recommendations for the treatment of isoniazid-resistant, rifampicin-susceptible TB are based upon a review of evidence from patients treated with such regimens by a Guideline Development Group in conformity with WHO requirements for evidence-based policies.
 External Link
 Add to my

Antidepressant drugs and generic counselling for treatment of major depression in primary care: randomised trial with patient preference arms

C. Chilvers, M. Dewey, K. Fielding, et al. (2001) CC
BMJ 2001;322:1–5
 Download
  View PDF
 Add to my

Emergency Use Designation of COVID-19 candidate vaccines: Ethical considerations for current and future COVID-19 placebo-controlled vaccine trials and trial unblinding

World Health Organization WHO (2020) C_WHO
The conduct of COVID-19 vaccine trials in the context of a candidate vaccine being issued with Emergency Use Designation raises challenging ethical questions, including in relation to the use of placebo controls and unblinding of trial participants ... more
 Download
  View PDF
 Add to my

WHO consolidated guidelines on tuberculosis: module 4: treatment: drug-resistant tuberculosis treatment,update

World Health Organization WHO (2022) C_WHO
These guidelines group all recommendations on TB care and support in one document and are complemented by an operational handbook. The guidelines are to be used primarily by national TB programmes, or their equivalents in Ministries of Health, stakeholders and technical organizations working on ... more
 Download
  View PDF
 Add to my

Mobile Tuberculosis Treatment Support Tools to Increase Treatment Success in Patients with Tuberculosis in Argentina: Protocol for a Randomized Controlled Trial

Iribarren, S.; Milligan H., Goodwin K., et al. (2021) CC
 Download
  View PDF
 Add to my

Policy Guidelines for Collaborative TB and HIV Services for Injecting and Other Drug Users: An Integrated Approach

World Health Organization, UNAIDS, United Nations Office on Drugs and Crime (2008)
These policy guidelines provide a strategic approach and new recommendations for integrated TB and HIV services for patients suffering from substance-abuse addiction. The key recommendations fall under three main categories: joint planning, key interventions, and overcoming barriers.
 Download
  View PDF
 Add to my

Prioritization of pathogens to guide discovery, research and development of new antibiotics for drug-resistant bacterial infections, including tuberculosis

World Health Organization (2017) C_WHO
 External Link
 Add to my

Combined Use of Delamanid and Bedaquiline to Treat Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: A Systematic Review

G. B. Migliori, E. Pontali, G. Sotgiu, et al. International Journal of Molecular Scienes (2017) C2
Int. J. Mol. Sci. 2017, 18, 341, 1 - 10
 Download
  View PDF
 Add to my

Diagnostic test for lymphatic filariasis to support decisions for stopping triple-therapy mass drug administration: target product profile

World Health Organization World Health Organization WHO (2021) C_WHO
TARGET PRODUCT PROFILE
 Download
  View PDF
 Add to my

The impact of residual infections on Anopheles-transmitted Wuchereria bancrofti after multiple rounds of mass drug administration

D. K. de Souza; Ansumana, R.; Sessay, S.; Parasites & Vectors (2015) CC
Many countries have made significant progress in the implementation of World Health Organization recommended preventive chemotherapy strategy, to eliminate lymphatic filariasis (LF). However, pertinent challenges such as the existence of areas of residual infections in disease endemic districts pose ... more
 Download
  View PDF
 Add to my

Community health workers to improve uptake of maternal healthcare services: A clusterrandomized pragmatic trial in Dar es Salaam, Tanzania

Geldsetzer, P.; Mboggo, E.; Larson, E.; et al. (2019) CC2
PLoS Med 16(3): e1002768. https://doi.org/10.1371/journal.pmed.1002768 Home delivery and late and infrequent attendance at antenatal care (ANC) are responsible for substantial avoidable maternal and pediatric morbidity and mortality in sub-Saharan Africa. This cluster-randomized ... more